IN8bio Appoints New Chief Medical Officer
Ticker: INAB · Form: 8-K · Filed: Nov 25, 2024 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 8-K |
| Filed Date | Nov 25, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, biotech, oncology
TL;DR
IN8bio just hired a new CMO, Dr. Lawrence M. Cohen. Big move for their oncology pipeline.
AI Summary
On November 25, 2024, IN8bio, Inc. filed an 8-K report detailing the appointment of Dr. Lawrence M. Cohen as Chief Medical Officer. Dr. Cohen brings extensive experience in oncology and cell therapy development to the company.
Why It Matters
The appointment of a new Chief Medical Officer with expertise in oncology and cell therapy could signal a strategic shift or acceleration in IN8bio's drug development pipeline.
Risk Assessment
Risk Level: medium — The appointment of a key executive like a Chief Medical Officer can impact the company's strategic direction and execution, carrying inherent risks.
Key Players & Entities
- IN8BIO, INC. (company) — Registrant
- Dr. Lawrence M. Cohen (person) — Newly appointed Chief Medical Officer
- November 25, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-39692 (identifier) — SEC File Number
FAQ
Who is the new Chief Medical Officer at IN8bio?
Dr. Lawrence M. Cohen has been appointed as the new Chief Medical Officer of IN8bio, Inc.
When was this appointment announced?
The appointment was disclosed in an 8-K filing dated November 25, 2024.
What is the primary focus of IN8bio, Inc. based on its SIC code?
IN8bio, Inc. is classified under SIC code 2836, indicating its business is in Biological Products (No Diagnostic Substances).
What is IN8bio's principal executive office address?
The company's principal executive offices are located at 350 5th Avenue, Suite 5330, New York, New York 10118.
What was IN8bio, Inc. formerly known as?
IN8bio, Inc. was formerly known as Incysus Therapeutics, Inc. until May 10, 2018.
Filing Stats: 446 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2024-11-25 07:09:29
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share INAB The Nasdaq
Filing Documents
- d844601d8k.htm (8-K) — 26KB
- d844601dex991.htm (EX-99.1) — 22KB
- g844601g1125020731832.jpg (GRAPHIC) — 2KB
- 0001193125-24-264714.txt ( ) — 181KB
- inab-20241125.xsd (EX-101.SCH) — 3KB
- inab-20241125_lab.xml (EX-101.LAB) — 18KB
- inab-20241125_pre.xml (EX-101.PRE) — 11KB
- d844601d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated November 25, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IN8bio, Inc. Dated: November 25, 2024 By: /s/ Patrick McCall Patrick McCall Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)